BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

PeptiDream, PDRadiopharma, and Curium Launch Registrational Phase 2 Trial in Japan for 64Cu-PSMA-I&T Targeting Prostate Cancer

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), PDRadiopharm...

October 17, 2025 | News

A.D.A.M. Innovations and SOPHiA GENETICS Partner to Advance AI-Driven Liquid Biopsy Cancer Testing in Japan

A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS , an AI technology company pioneering data-d...

October 17, 2025 | News

Jacobio Pharma Partners with Oceanpine Capital in RMB 200 Million Equity Deal for Cardiovascular Research Subsidiary

Jacobio Pharma announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity...

October 16, 2025 | News

Everest Medicines Secures Dual IND Approvals for EVM14, Its First Internally Developed Therapeutic mRNA Cancer Vaccine

EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medic...

October 14, 2025 | News

Anthony Elgamal: Redefining First-Line Treatment in EGFR-Mutated Lung Cancer

BioPharma APAC speaks with Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific, on th...

October 13, 2025 | Expert Insight

C-Ray Therapeutics Commends Biokin on NMPA Approval for Groundbreaking [177Lu]-BL-ARC001 Radiopharmaceutical

C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the N...

October 13, 2025 | News

Kazia Therapeutics Partners with QIMR Berghofer to Develop First-in-Class PD-L1 Degrader NDL2

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced an exclusive collaboration and in-licensing agreem...

October 09, 2025 | News

Redefining Cancer Care in Southeast Asia: Siemens Healthineers’ Fabrice Leguet on Turning Awareness into Action

Cancer care in Southeast Asia stands at a critical crossroads. While awareness of early detection is high, the translation into meaningful action remains p...

October 01, 2025 | Interaction | By arcilla.fran@biopharmaapac.com

Daiichi Sankyo and AstraZeneca’s ENHERTU delivers second positive phase 3 win in HER2 positive early breast cancer

Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become...

September 30, 2025 | News

Noul Secures FDA Registration for miLab™ CER Cervical Cancer Diagnostic, Paving Way for US Market Entry

Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced that FDA registration has been completed...

September 26, 2025 | News

Lunit and CellCarta Form Global Partnership to Advance AI-Powered Pathology in Clinical Trials

Lunit , a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, announced a strategic partnership with CellCarta, a globa...

September 25, 2025 | News

Lunit and Agilent Forge Collaboration to Develop AI-Powered Companion Diagnostics

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabili...

September 23, 2025 | News

Johnson & Johnson’s Amivantamab–Lazertinib Combo Extends Survival Beyond Four Years in Asia NSCLC Cohort

Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more th...

September 17, 2025 | News

Japan Approves Novocure’s Optune Lua for Concurrent Use with PD-1/PD-L1 Inhibitors in Advanced NSCLC

Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on...

September 17, 2025 | News

Stay Connected